文献速递垂体与肾上腺疾病

肾脏疾病中11β-羟基类固醇脱氢酶2活性受损破坏11-氧化雄激素生物合成

Impaired 11β-Hydroxysteroid Dehydrogenase Type 2 Activity in Kidney Disease Disrupts 11-Oxygenated Androgen Biosynthesis.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

该横断面观察性研究纳入慢性肾脏病(CKD)患者85例和健康对照46例,用液相色谱串联质谱测定血清和尿液中糖皮质激素及经典与11-氧化雄激素浓度,并用计算模型拟合血清数据。结果显示CKD患者皮质醇/可的松比值高于对照(P < .0001),血清可的松、11-酮雄烯二酮、11-酮睾酮和11β-羟基睾酮浓度均低于对照(各P < .0001),计算模型确认HSD11B2是CKD中11-氧化雄激素生物合成减少的关键酶,预测的HSD11B2表达与eGFR相关。

要点

  • CKD患者皮质醇/可的松比值高于健康对照(P < .0001),提示HSD11B2活性下降。
  • CKD患者血清可的松、11-酮雄烯二酮、11-酮睾酮和11β-羟基睾酮浓度均低于对照(各P < .0001)。
  • 计算模型确认HSD11B2是CKD中11-氧化雄激素生物合成减少的关键酶,预测表达与eGFR相关。

核心结论

  • 这是首个在体内确认肾脏HSD11B2在11-氧化雄激素生物合成中起核心作用的研究。
  • 确定该观察对CKD患者的临床意义需要进一步研究。

研究设计与样本

  • 横断面观察性研究,纳入CKD患者85例和健康对照46例。
  • 用液相色谱串联质谱测定血清和尿液中糖皮质激素及经典与11-氧化雄激素浓度。
  • 将外周11-氧化雄激素生物合成的计算模型拟合血清数据,计算每位参与者的相对HSD11B2表达水平。

主要发现

  • CKD患者皮质醇/可的松比值高于健康对照(P < .0001),HSD11B2活性随估算肾小球滤过率(eGFR)下降而降低。
  • CKD患者血清可的松、11-酮雄烯二酮、11-酮睾酮和11β-羟基睾酮浓度均低于健康对照(各P < .0001)。
  • 基于HSD11B2、11β-羟基类固醇脱氢酶1型、17β-羟基类固醇脱氢酶2型和醛酮还原酶1C3酶动力学参数的计算模型确认HSD11B2是CKD中11-氧化雄激素生物合成减少的关键酶。
  • 预测的HSD11B2表达与eGFR相关。

局限性

  • 确定该观察对CKD患者的临床意义需要进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: 11-Oxygenated androgens are a group of adrenal-derived steroids that require peripheral activation. In vitro data highlight a putative role for 11β-hydroxysteroid dehydrogenase type 2 (HSD11B2) in 11-oxygenated androgen biosynthesis, converting 11β-hydroxyandrostenedione to 11-ketoandrostenedione (11KA4), the direct precursor of the potent androgen 11-ketotestosterone (11KT). As the kidney is the major site of HSD11B2 expression, we hypothesized that patients with chronic kidney disease (CKD) would have reduced 11-oxygenated androgen biosynthesis due to impaired HSD11B2 activity. OBJECTIVE: To determine the role of HSD11B2 in 11-oxygenated androgen biosynthesis using a human CKD cohort alongside complementary cell culture and computational modeling approaches. METHODS: Cross-sectional observational study of patients with CKD (n = 85) and healthy controls (n = 46) measuring serum and urinary concentrations of glucocorticoids, and classic and 11-oxygenated androgens by liquid chromatography tandem mass spectrometry. A computational model of peripheral 11-oxygenated androgen biosynthesis was fitted to the serum data to calculate relative HSD11B2 expression levels for each participant. RESULTS: HSD11B2 activity declined with estimated glomerular filtration rate (eGFR), evidenced by higher cortisol/cortisone (E) ratios in patients with CKD than in controls (P < .0001). Serum concentrations of E, 11KA4, 11KT, and 11β-hydroxytestosterone were lower in patients with CKD than in controls (P < .0001 for each). A computational model based on enzyme kinetic parameters of HSD11B2, 11β-hydroxysteroid dehydrogenase type 1, 17β-hydroxysteroid dehydrogenase type 2, and aldo-keto reductase 1C3 confirmed HSD11B2 as the key enzyme responsible for reduced 11-oxygenated androgen biosynthesis in CKD. Predicted HSD11B2 expression correlated with eGFR. CONCLUSION: This is the first in vivo study to confirm a central role for renal HSD11B2 in 11-oxygenated androgen biosynthesis. Determining the clinical implications of this observation for patients with CKD requires further research.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Tomkins M, McDonnell T, Cussen L, et al. Impaired 11β-Hydroxysteroid Dehydrogenase Type 2 Activity in Kidney Disease Disrupts 11-Oxygenated Androgen Biosynthesis. J Clin Endocrinol Metab. 2025. PMID: 39382395. doi:10.1210/clinem/dgae714

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。